Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2020

01-01-2020 | Editorial

Future of Haemophilia Research in India

Authors: Kanjaksha Ghosh, Rinku Shukla

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2020

Login to get access

Excerpt

Haemophilia represents high cost low volume disease [1]. Hence in developing countries in the world where 90 % of haemophilia patients lives puts the government of the day in a conundrum ie the limited resources of that country earmarked for health needs to be distributed amongst management and prevention of various diseases which optimally helps the population of the country. Hence there is a need for developing research protocols suitable for that country in an evidence based manner. Haemophilia research in India is one of the examples of need based research, often driven by patients organizations ie Haemophilia federation of India [2]. In last 30 years large number of research papers in haemophilia has contributed materially to our diagnostics, management and training of manpower in the country [3]. …
Literature
1.
Ghosh K, Ghosh K (2016) Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 32(3):347–355CrossRef
2.
Ghosh K, Shetty S, Sahu D (2010) Haemophilia care in India: innovations and integrations by various chapters of Haemophilia Federation of India (HFI). Haemophilia 16(1):61–65CrossRef
3.
Ghosh K (2004) Management of haemophilia and its complications in developing countries. Clin Lab Haematol 26(4):243–251CrossRef
4.
Ghosh K, Ghosh K, Shetty S (2012) Hemostasis research in India: past, present, and future. Clin Appl Thromb Hemost 18(2):128–133CrossRef
5.
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V et al (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 374:2054–2064CrossRef
6.
Shetty S, Shelar T, Mirgal D, Nawadkar V, Pinto P, Shabhag S et al (2014) Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 20(4):575–581CrossRef
7.
Shetty S, Ghosh K (2012) Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers: a rebuttal. J Thromb Haemost 10(6):1200–1201CrossRef
8.
Shetty S, Sharma N, Ghosh K (2016) Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. Crit Rev Oncol Hematol 99:129–133CrossRef
9.
Sen D, Balakrishnan B, Gabriel N, Agrawal P, Roshini V, Samuel R et al (2013) Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep 3:1832CrossRef
10.
Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros L, Ghosh K (2007) Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 138(4):541–544CrossRef
11.
Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T et al (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21(5):492–497CrossRef
12.
Nair PS, Shetty S, Ghosh K (2016) Factor VIII antigen, activity, and mutations in hemophilia A. Clin Appl Thromb Hemost 22(4):381–385CrossRef
13.
Shetty S, Ghosh K, Jijina F (2006) First-trimester prenatal diagnosis in haemophilia A and B families—10 years experience from a centre in India. Prenat Diagn 26(11):1015–1017CrossRef
14.
Ranjan R, Biswas A, Kannan M, Meena A, Deka D, Saxena R (2007) Prenatal diagnosis of haemophilia A by chorionic villus sampling and cordocentesis: all India Institute of Medical Science experience. Vox Sang 92(1):79–84CrossRef
15.
Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu D, Biswal N et al (2016) A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia—a success story from a resource limited country. Haemophilia 22(3):342–348CrossRef
16.
Kundu T, Shaikh A, Kutty A, Nalvade A, Kulkarni S, Kulkarni R, Ghosh K (2012) Homeopathic medicines substantially reduce the need for clotting factor concentrates in haemophilia patients: results of a blinded placebo controlled cross over trial. Homeopathy 101(1):38–43CrossRef
17.
Yadav N, Kanjirakkuzhiyil S, Kumar S, Jain M, Halder A, Saxena R, Mukhopadhyay A (2009) The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A. Blood 114(20):4552–4561CrossRef
18.
Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ et al (2017) Hemophilia liver transplantation observational study. Liver Transpl 23(6):762–768CrossRef
Metadata
Title
Future of Haemophilia Research in India
Authors
Kanjaksha Ghosh
Rinku Shukla
Publication date
01-01-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0872-2

Other articles of this Issue 1/2020

Indian Journal of Hematology and Blood Transfusion 1/2020 Go to the issue

Correspondence

From Oncologist’s Desk: Hemato-Oncological Aspect of Using Vaporizers, E-Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS)

Original Article

TET2 Single Nucleotide Polymorphism in Myeloid Neoplasms Among Egyptian Patients

Original Article

Clinical Characteristics and Treatment Outcome of Hypocellular Acute Myeloid Leukemia Based on WHO Classification

Correspondence

Hemoglobin Henri Mondor [β26(B8) Glu → Val, GAG > GTG], A First Case Report in South-East Asia

Review Article

Low Dose Prophylaxis in Hemophilia Care

Short Communication

Cluster of Differentiation 96 in Children with Acute Leukemia: A Single Center Cohort Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits